Hepatitis C virus infection and isoniazid hepatotoxicity [5]

Chest

Volumn 132, Issue 2, 2007, Pages 736-

  Fernandez Villar, Alberto ^a   Leiro, Virginia ^a   Botana, Maribel ^a   Sopeña, Bernardo ^a  

^a HOSPITAL XERAL CÍES   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; ISONIAZID; TUBERCULOSTATIC AGENT;

AMINOTRANSFERASE BLOOD LEVEL; COMORBIDITY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LETTER; LIVER TOXICITY; PRIORITY JOURNAL; SIDE EFFECT; SUPERINFECTION; TUBERCULOSIS;

EID: 34548008172     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.07-0866     Document Type: Letter

References (6)

1. Kwon YS, Koh W, Suh GY, et al. Hepatitis C virus infection and hepatotoxicity during antituberculosis chemotherapy. Chest 2007; 131:803-808
2. Sadaphal P, Astemborski J, Graham NM, et al. Isoniazid preventive therapy, hepatitis C virus infection, and hepatotoxicity among injection drug users infected with Mycobacterium tuberculosis. Clin Infect Dis 2001; 33:1687-1691
3. Fernandez-Villar A, Sopena B, Vazquez R, et al. Isoniazid hepatotoxicity among drug users: the role of hepatitis C. Clin Infect Dis 2003; 36:293-298
4. Ungo JR, Jones D, Ashkin D, et al. Antituberculosis drug-induced hepatotoxicity: the role of hepatitis C virus and the human immunodeficiency virus. Am J Respir Crit Care Med 1998; 157:1871-1876
5. Fernández-Villar A, Sopeña B, García J, et al. Hepatitis C virus RNA in serum as a risk factor for isoniazid hepatotoxicity. Infection 2007 (in press)
6. Schenker S, Martin RR, Hoyumpa A. Antecedent liver disease and drug hepatotoxicity. J Hepatol 1999; 31:1098-1105